- Guselkumab (Tremfya), an IL-23 inhibitor, is associated with superior skin clearance vs secukinumab (Cosentyx), an IL-17A inhibitor, in patients with moderate to severe psoriasis, according to results from the phase 3 ECLIPSE trial.
Why this matters
- Several treatment options for psoriasis have recently become available, necessitating head-to-head trials.
- Guselkumab was associated with a superior rate of ≥90% improvement in the Psoriasis Area and Severity Index (PASI 90) compared with secukinumab at week 48 (primary endpoint).
- 84% vs 70% (P<.0001 in intent-to-treat analysis.>
- 88% vs 76% (P<.0001 in per protocol analysis>
- The most common adverse events were nasopharyngitis (22% in the guselkumab group, 24% in the secukinumab group) and upper respiratory tract infection (16% in the guselkumab group, 18% in the secukinumab group).
- 1048 patients with moderate to severe psoriasis (534 who received guselkumab and 514 who received secukinumab) were analyzed for outcomes.
- Funding: Janssen Research & Development.
- No assessments of drug concentration and antibody data for secukinumab.